United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

bowmed ibisqus ltd - ceftazidime pentahydrate - powder for solution for injection - 2gram

United States - English - NLM (National Library of Medicine)

teligent pharma, inc. - ceftazidime (unii: 9m416z9qnr) (ceftazidime anhydrous - unii:dzr1ent301) - ceftazidime anhydrous 200 mg in 1 ml - fortaz is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases: fortaz may be used alone in cases of confirmed or suspected sepsis. ceftazidime has been used successfully in clinical trials as empiric therapy in cases where various concomitant therapies with other antibacterial drugs have been used. fortaz may also be used concomitantly with other antibacterial drugs, such as aminoglycosides, vancomycin, and clindamycin; in severe and life-threatening infections; and in the immunocompromised patient. when such concomitant treatment is appropriate, prescribing information in the labeling for the other antibacterial drugs should be followed. the dose depends on the severity of the infection and the patient's condition. to reduce the development of drug-resistant bacteria and maintain the effectiveness of fortaz and other antibacterial drugs, fortaz should be used only to treat infections that are proven or strongly suspected

United States - English - NLM (National Library of Medicine)

hospira, inc. - ceftazidime (unii: 9m416z9qnr) (ceftazidime anhydrous - unii:dzr1ent301) - ceftazidime anhydrous 1 g - tazicef (ceftazidime for injection, usp) is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases: tazicef (ceftazidime for injection, usp) may be used alone in cases of confirmed or suspected sepsis. ceftazidime has been used successfully in clinical trials as empiric therapy in cases where various concomitant therapies with other antibacterial drugs have been used. tazicef (ceftazidime for injection, usp) may also be used concomitantly with other antibacterial drugs, such as aminoglycosides, vancomycin, and clindamycin; in severe and life-threatening infections; and in the immunocompromised patient. when such concomitant treatment is appropriate, prescribing information in the labeling for the other antibacterial drugs should be followed. the dose depends on the severity of the infection and the patient's condition. to reduce the development of drug-resistant bacteria and maintain the effectiveness of tazicef (ceftazidime

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - ceftazidime pentahydrate -

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - ceftazidime pentahydrate 1.164 g equivalent to ceftazidime 1.0 g - powder for injection - 1 g - active: ceftazidime pentahydrate 1.164 g equivalent to ceftazidime 1.0 g excipient: sodium carbonate - indicated for the treatment of single and mixed infections caused by susceptible aerobic organisms with suspected or documented resistance to other antimicrobials, but not to ceftazidime, and as an alternative to aminoglycoside in pseudomonal infection in patients in whom aminoglycoside toxicity is a cause for concern and other pseudomonal antibiotics cannot be used. indications include: - severe infections in general: for example septicaemia, including neonatal sepsis, bacteraemia, and in patients in intensive care units with specific problems, for example infected burns. - respiratory tract infections: for example, pneumonia, broncho-pneumonia, infected pleurisy, infected bronchiectasis and bronchitis. - severe ear, nose and throat infections: for example, otitis media, mastoiditis. - urinary tract infections: for example, acute and chronic pyelonephritis, pyelitis, cystitis, urethritis (bacterial only), and infections associated with bladder and renal stones. - skin and soft tissue infections: for example, erysipelas, abscesses, cellulitis, infected burns and wounds, mastitis. - gastrointestinal and abdominal infections: for example, intra-abdominal abscesses, enterocolitis. - bone and joint infections: for example, osteitis, osteomyelitis, septic arthritis, infected bursitis. - infections associted with haemo- and peritoneal dialysis and with continuous ambulatory peritoneal dialysis (capd)

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - ceftazidime pentahydrate 2.329 g equivalent to ceftazidime 2.0 g - powder for injection - 2 g - active: ceftazidime pentahydrate 2.329 g equivalent to ceftazidime 2.0 g excipient: sodium carbonate - indicated for the treatment of single and mixed infections caused by susceptible aerobic organisms with suspected or documented resistance to other antimicrobials, but not to ceftazidime, and as an alternative to aminoglycoside in pseudomonal infection in patients in whom aminoglycoside toxicity is a cause for concern and other pseudomonal antibiotics cannot be used. indications include: - severe infections in general: for example septicaemia, including neonatal sepsis, bacteraemia, and in patients in intensive care units with specific problems, for example infected burns. - respiratory tract infections: for example, pneumonia, broncho-pneumonia, infected pleurisy, infected bronchiectasis and bronchitis. - severe ear, nose and throat infections: for example, otitis media, mastoiditis. - urinary tract infections: for example, acute and chronic pyelonephritis, pyelitis, cystitis, urethritis (bacterial only), and infections associated with bladder and renal stones. - skin and soft tissue infections: for example, erysipelas, abscesses, cellulitis, infected burns and wounds, mastitis. - gastrointestinal and abdominal infections: for example, intra-abdominal abscesses, enterocolitis. - bone and joint infections: for example, osteitis, osteomyelitis, septic arthritis, infected bursitis. - infections associted with haemo- and peritoneal dialysis and with continuous ambulatory peritoneal dialysis (capd)

Malta - English - Medicines Authority

villerton invest s.a. rue edward steichen 14, 2540, luxembourg - ceftazidime - powder for solution for injection - ceftazidime 500 mg - antibacterials for systemic use

Malta - English - Medicines Authority

villerton invest s.a. - ceftazidime - powder for solution for injection - ceftazidime 1 g - antibacterials for systemic use

Malta - English - Medicines Authority

villerton invest s.a. rue edward steichen 14, 2540, luxembourg - ceftazidime - powder for solution for injection - ceftazidime 2 g - antibacterials for systemic use

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - ceftazidime pentahydrate -